Evidence map›Paper›PMID 41557106›Full record

ArticleDiscover oncology2026

Durable response to immunotherapy in NSCLC with duodenal metastasis.

Yufei Li, Leichong Chen, Yijin Li, Qiang Luo, Shuang You, Yan Zong, Qianwen Li, Shaoxian Cheng, Rui Meng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yufei Li *Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
Leichong Chen *Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
Yijin Li *Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
Qiang LuoCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
Shuang YouCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
Yan ZongCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
Qianwen LiCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
Shaoxian ChengDepartment of General Surgery, Jingshan Union Hospital, Union Hospital, Huazhong University of Science and Technology, Jingshan, China. 123csx456@163.com.
Rui MengCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China. mengruivip@163.com.

Funding

Beijing Xisike Clinical Oncology Research Foundation No. Y-zai2022/ms-0190 and Y-2024AZ(EGFR)MS-0041Chinese Thoracic Oncology Group No. CTONG-YC20220118National Natural Science Foundation of China No. 82373228Natural Science Foundation of Hubei Province of China No.2024AFD440
6 · The paper itself

Abstract

Lung cancer is the leading cause of tumor-related death in the world. Duodenal metastasis from lung adenocarcinoma is an exceptionally rare occurrence and is often asymptomatic. Currently, there are no FDA-approved, well-defined treatment guidelines for this patient subgroup, and clinical studies in this area are scarce, limited to several case reports. Further investigation is needed to identify suitable treatments for this group. Here, we present a case of lung adenocarcinoma with duodenal metastases in a patient who exhibited a notable clinical response to immunotherapy over 39 months. Due to the limited data available on duodenal metastases from lung adenocarcinoma, this case highlights the challenges faced by clinicians in managing such cases and provides new ideas for future management of the disease.

Indexed as

Duodenal metastasisImmunotherapyNSCLC

Identifiers

PMID41557106
PMCPMC12905014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.